Tech & Pharma
BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia® for the treatment of rheumatoid arthritis in China.
Global chemical company, BASF, plans to invest €10 billion in Asia from 2013-2020, as part of the company’s Asia Pacific strategy.
FUJIFILM and Dr. Reddy’s Laboratories have terminated an MOU to enter into a joint venture for the Japanese generics drugs market.
PAREXEL International Corporation opened in May a new office in Shenyang, China to support client demand for clinical development capabilities in the region.
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
EBOS Group Limited announced this week details of a NZ$1.1 billion acquisition of Australia’s Symbion.
ASLAN Pharma announced this week positive data with ASLAN001 in a gastric cancer Phase II study.
The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.
Amgen and Astellas Pharma Inc. today announced a strategic alliance to co-develop and co-commercialize new medicines in Japan.
A*STAR’s GIS and Sengenics will partner on cancer biomarker discovery with the aim of identifying and validating auto-antibodies that can be used to detect early-stage cancers.